论文部分内容阅读
以CsAPred二联用于肾移植已经十年,近来由于长期应用CsA导致潜在不可逆肾毒性而引入了三联方案(小剂量CsA-Aza-Pred)。众多报道均表明两种方案的人、肾存活率无差异,但三联方案的感染率明显升高。本文旨在比较两种方案尤其在感染和急性排斥发病率的不同。以19874～1989.11间大于13岁的102例尸体肾移植病人作回顾性分析,本研究只包括91例至少应用三联(小剂量CsA·Aza Pred)或二联(CsA-Pred)30天的病人,除外另11例术后30天内移植肾丧失或免疫
A two-factor CsAPred combination has been used for kidney transplantation for ten years and a triple regimen (low-dose CsA-Aza-Pred) has recently been introduced due to potential irreversible nephrotoxicity caused by long-term use of CsA. Numerous reports have shown that there is no difference in the survival rate between the two groups of patients, but the infection rate of the triple combination is significantly higher. This article aims to compare the differences between the two programs, especially in the incidence of infection and acute rejection. A retrospective analysis was performed on 102 cadaveric kidney transplant patients aged 13 years or older between 19874 and 1989.11 The study included only 91 patients who had received at least triple CsA or Aza Pred or CsA-Pred for 30 days, Except for the other 11 cases, the graft was lost or immunized within 30 days after operation